BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 24225338)

  • 1. Comparison of effects of α-Glucosidase inhibitors and glinide drugs on endothelial dysfunction in diabetic patients with coronary artery disease.
    Sawada T; Shiotani H; Terashita D; Nagasawa Y; Kim SS; Koide M; Yokoyama M
    Circ J; 2014; 78(1):248-55. PubMed ID: 24225338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single administration of alpha-glucosidase inhibitors on endothelial function and incretin secretion in diabetic patients with coronary artery disease - Juntendo University trial: effects of miglitol on endothelial vascular reactivity in type 2 diabetic patients with coronary heart disease (J-MACH) -.
    Hiki M; Shimada K; Kiyanagi T; Fukao K; Hirose K; Ohsaka H; Fukushima Y; Kume A; Matsumori R; Sumiyoshi K; Miyazaki T; Ohmura H; Kurata T; Miida T; Daida H
    Circ J; 2010 Jul; 74(7):1471-8. PubMed ID: 20519875
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery disease.
    Emoto T; Sawada T; Hashimoto M; Kageyama H; Terashita D; Mizoguchi T; Mizuguchi T; Motodi Y; Iwasaki M; Taira K; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
    Am J Cardiol; 2012 Jan; 109(1):42-6. PubMed ID: 21944671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 6-month eicosapentaenoic acid treatment on postprandial hyperglycemia, hyperlipidemia, insulin secretion ability, and concomitant endothelial dysfunction among newly-diagnosed impaired glucose metabolism patients with coronary artery disease. An open label, single blinded, prospective randomized controlled trial.
    Sawada T; Tsubata H; Hashimoto N; Takabe M; Miyata T; Aoki K; Yamashita S; Oishi S; Osue T; Yokoi K; Tsukishiro Y; Onishi T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H; Yokoyama M
    Cardiovasc Diabetol; 2016 Aug; 15(1):121. PubMed ID: 27565734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study.
    Kato T; Inoue T; Node K
    Cardiovasc Diabetol; 2010 Mar; 9():12. PubMed ID: 20334663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prandial glucose regulator and insulin secretagogue; glinide and its combination therapy].
    Nakashima E
    Nihon Rinsho; 2015 Mar; 73(3):416-23. PubMed ID: 25812367
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of acute and chronic attenuation of postprandial hyperglycemia on postglucose-load endothelial function in insulin resistant individuals: is stimulation of first phase insulin secretion beneficial for the endothelial function?
    Major-Pedersen A; Ihlemann N; Hermann TS; Christiansen B; Kveiborg B; Dominguez H; Nielsen D; Rask-Madsen C; Svendsen OL; Køber L; Torp-Pedersen C
    Horm Metab Res; 2008 Sep; 40(9):607-13. PubMed ID: 18792871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single dose of nateglinide improves post-challenge glucose metabolism and endothelial dysfunction in Type 2 diabetic patients.
    Shimabukuro M; Higa N; Takasu N; Tagawa T; Ueda S
    Diabet Med; 2004 Sep; 21(9):983-6. PubMed ID: 15317602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Miglitol improves postprandial endothelial dysfunction in patients with acute coronary syndrome and new-onset postprandial hyperglycemia.
    Kitano D; Chiku M; Li Y; Okumura Y; Fukamachi D; Takayama T; Hiro T; Saito S; Hirayama A
    Cardiovasc Diabetol; 2013 Jun; 12():92. PubMed ID: 23777506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Glinide(s), sulfonylurea(s)].
    Arakawa M; Hirose T
    Nihon Rinsho; 2006 Nov; 64(11):2107-12. PubMed ID: 17087304
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Dangerous postprandial glucose peaks. Risk for heart and blood vessels].
    MMW Fortschr Med; 2002 May; 144(21):58. PubMed ID: 12134432
    [No Abstract]   [Full Text] [Related]  

  • 12. Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide.
    Mari A; Gastaldelli A; Foley JE; Pratley RE; Ferrannini E
    Diabetes Care; 2005 May; 28(5):1132-8. PubMed ID: 15855578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the administration of a single dose of nateglinide on insulin secretion at two different concentrations of glucose in healthy individuals.
    González-Ortiz M; Hernández-Salazar E; Martínez-Abundis E
    J Diabetes Complications; 2005; 19(6):356-60. PubMed ID: 16260353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide.
    Scheen AJ
    Clin Pharmacokinet; 2007; 46(2):93-108. PubMed ID: 17253883
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia.
    Hanefeld M; Bouter KP; Dickinson S; Guitard C
    Diabetes Care; 2000 Feb; 23(2):202-7. PubMed ID: 10868832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of insulin secretion pattern lectured by "glinides" in the treatment of postprandial hyperglycemia].
    Hirose T
    Nihon Rinsho; 2005 Dec; 63(12):2237-44. PubMed ID: 16363700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Empagliflozin's Ameliorating Effect on Plasma Triglycerides: Association with Endothelial Function Recovery in Diabetic Patients with Coronary Artery Disease.
    Sawada T; Uzu K; Hashimoto N; Onishi T; Takaya T; Shimane A; Taniguchi Y; Yasaka Y; Ohara T; Kawai H
    J Atheroscler Thromb; 2020 Jul; 27(7):644-656. PubMed ID: 31631099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological treatment of postprandial hyperglycemia in hypertensive patients with type 2 diabetes mellitus].
    Yamada K
    Nihon Rinsho; 2003 Jul; 61(7):1219-23. PubMed ID: 12877088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The alpha-glucosidase inhibitor miglitol affects bile acid metabolism and ameliorates obesity and insulin resistance in diabetic mice.
    Hamada Y; Nagasaki H; Fuchigami M; Furuta S; Seino Y; Nakamura J; Oiso Y
    Metabolism; 2013 May; 62(5):734-42. PubMed ID: 23194643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of α-glucosidase inhibitors on postprandial plasma glucose and lipid profile in patients with type 2 diabetes under control with insulin lispro mix 50/50.
    Kimura T; Suzuki J; Ichikawa M; Imagawa M; Sato S; Fujii M; Zenimaru Y; Inaba S; Takahashi S; Konoshita T; Miyamori I
    Diabetes Technol Ther; 2012 Jul; 14(7):545-51. PubMed ID: 22519736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.